Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...

Key Takeaways Novo Nordisk is lowering the price of its weight-loss drug Wegovy to $499 per month for some patients paying ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk is cutting the price of its weight-loss drug, Wegovy, and selling it through a direct-to-patient online pharmacy ...

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...

Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.

Novo Nordisk A/S (NVO) has lowered prices of its blockbuster drug Wegovy for U.S. customers through a new direct-to-consumer online pharmacy, ...

The weight-loss drug can cost patients more than $1,000 a month if they do not have health insurance coverage.